Dave CV, et al. - Researchers used US-based administrative-claims data (July 2013 to June 2018) to assess recent changes in clinical and prescriber features of patients starting sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA). According to results, empagliflozin initiation (as a proportion of SGLT2i) rose by 57.1% whereas canagliflozin initiation decreased by 75.1% over 5 years. The only agent within SGLT2i with an increase in the proportion of patients with myocardial infarction, stroke, or heart failure (collectively called CVD-HF) was empagliflozin. For SGLT2i, shifts in preference for empagliflozin followed changes in drug labels and guidelines, on the other hand, in GLP-1RA, other factors like price or ease of administration might have contributed to dulaglutide preference over liraglutide.